



PRODUCT: **Nubeqa®**

COMPANY: Bayer

THERAPEUTIC AREA & INDICATION:

For patients with non-metastatic castration-resistant prostate cancer

ABOUT THE PRODUCT

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. We support efforts to overcome the major challenges presented by a growing and aging global population. In prostate cancer, the second most common cancer in men, we are transforming the standard of care with products that focus on delaying metastases, survival, and tolerability. In precision oncology, Bayer is paving the way with the global introduction of a first-in-class oral TRK inhibitor exclusively designed to treat the driver that causes the cancer to spread and grow, rather than treat where the tumor originates in the body, in adults and children.